230 related articles for article (PubMed ID: 26451276)
21. Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure.
Hahn S; Ayav A; Lopez A
Case Rep Gastroenterol; 2017; 11(2):422-427. PubMed ID: 29033758
[TBL] [Abstract][Full Text] [Related]
22. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer.
de Jesus VHF; Camandaroba MPG; Calsavara VF; Riechelmann RP
Ther Adv Med Oncol; 2020; 12():1758835920905408. PubMed ID: 32165927
[TBL] [Abstract][Full Text] [Related]
23. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD
J Gastrointest Oncol; 2016 Jun; 7(3):469-78. PubMed ID: 27284481
[TBL] [Abstract][Full Text] [Related]
24. Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer.
Rehman H; Chi J; Hakim N; Goyal SP; Olazagasti C; Jose J; Moriarty L; Saif MW
Therap Adv Gastroenterol; 2020; 13():1756284820974912. PubMed ID: 33281939
[TBL] [Abstract][Full Text] [Related]
25. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
[TBL] [Abstract][Full Text] [Related]
26. Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
Hegewisch-Becker S; Aldaoud A; Wolf T; Krammer-Steiner B; Linde H; Scheiner-Sparna R; Hamm D; Jänicke M; Marschner N;
Int J Cancer; 2019 Mar; 144(5):981-990. PubMed ID: 30006989
[TBL] [Abstract][Full Text] [Related]
27.
Tabernero J; Kunzmann V; Scheithauer W; Reni M; Shiansong Li J; Ferrara S; Djazouli K
Onco Targets Ther; 2017; 10():591-596. PubMed ID: 28203092
[TBL] [Abstract][Full Text] [Related]
28. First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age.
Petrillo A; Pappalardo A; Calabrese F; Tirino G; Pompella L; Ventriglia J; Laterza MM; Caterino M; Sforza V; Iranzo V; Biglietto M; Orditura M; Ciardiello F; Conzo G; Molino C; De Vita F
J Gastrointest Oncol; 2019 Oct; 10(5):910-917. PubMed ID: 31602329
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis.
de Jesus VHF; Riechelmann RP
Ecancermedicalscience; 2021; 15():1276. PubMed ID: 34567261
[TBL] [Abstract][Full Text] [Related]
30. Real‑world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real‑world data project.
Shimoyama R; Imamura Y; Uryu K; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Ohtani K; Shinozaki N; Minami H
Mol Clin Oncol; 2023 Dec; 19(6):98. PubMed ID: 37953858
[TBL] [Abstract][Full Text] [Related]
31. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer.
Han SY; Kim DU; Seol YM; Kim S; Lee NK; Hong SB; Seo HI
World J Clin Cases; 2020 Sep; 8(17):3718-3729. PubMed ID: 32953848
[TBL] [Abstract][Full Text] [Related]
32. Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma.
Domadia K; Goel V; Koyyala VPB; Patnaik N; Chaudhari K; Raina S; Doval DC; Talwar V
South Asian J Cancer; 2022 Jan; 11(1):31-35. PubMed ID: 35833047
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.
Liu GF; Li GJ; Zhao H
J Cell Biochem; 2018 Jan; 119(1):511-523. PubMed ID: 28608558
[TBL] [Abstract][Full Text] [Related]
34. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.
Ahn DH; Krishna K; Blazer M; Reardon J; Wei L; Wu C; Ciombor KK; Noonan AM; Mikhail S; Bekaii-Saab T
Ther Adv Med Oncol; 2017 Feb; 9(2):75-82. PubMed ID: 28203300
[TBL] [Abstract][Full Text] [Related]
35. Comparative effectiveness and safety of
Mudad R; Patel MB; Margunato-Debay S; Garofalo D; Lal LS
Lung Cancer (Auckl); 2017; 8():179-190. PubMed ID: 29089791
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study.
Williet N; Petrillo A; Roth G; Ghidini M; Petrova M; Forestier J; Lopez A; Thoor A; Weislinger L; De Vita F; Taieb J; Phelip JM
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199796
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review.
Napolitano F; Formisano L; Giardino A; Girelli R; Servetto A; Santaniello A; Foschini F; Marciano R; Mozzillo E; Carratù AC; Cascetta P; De Placido P; De Placido S; Bianco R
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31337045
[TBL] [Abstract][Full Text] [Related]
38. The
Palacio S; Hosein PJ; Reis I; Akunyili II; Ernani V; Pollack T; Macintyre J; Restrepo MH; Merchan JR; Rocha Lima CM
J Gastrointest Oncol; 2018 Feb; 9(1):135-139. PubMed ID: 29564179
[TBL] [Abstract][Full Text] [Related]
39. Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients.
Merz V; Cavaliere A; Messina C; Salati M; Zecchetto C; Casalino S; Milella M; Caffo O; Melisi D
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32366019
[TBL] [Abstract][Full Text] [Related]
40. Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX.
de Jesus VHF; Camandaroba MPG; Donadio MDS; Cabral A; Muniz TP; de Moura Leite L; Sant'Ana LF
J Gastrointest Oncol; 2018 Oct; 9(5):806-819. PubMed ID: 30505579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]